Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Prostate Cancer

  Free Subscription


1 Acta Radiol
1 Cancer
1 Clin Cancer Res
1 Discov Oncol
1 Eur Urol
1 Hum Pathol
2 J Urol
1 Oncogene
1 Ther Adv Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Radiol

  1. STEVENS WM, Parchment-Smith C, Melling PP, Smith JT, et al
    Making an art into a science: a mathematical "Likert tool" can change PI-RADS (v2) scores into Likert scores when reporting multiparametric MRI for prostate cancer.
    Acta Radiol. 2022 Jul 11:2841851221112194. doi: 10.1177/02841851221112194.
    PubMed         Abstract available


  2. FANG AM, Shumaker LA, Martin KD, Jackson JC, et al
    Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions.
    Cancer. 2022 Jul 12. doi: 10.1002/cncr.34355.
    PubMed         Abstract available

    Clin Cancer Res

  3. AGGARWAL R, Starodub AN, Koh BD, Xing G, et al
    Phase 1b Study of the BET Inhibitor GS-5829 as Monotherapy and Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2022 Jul 11. pii: 706956. doi: 10.1158/1078-0432.CCR-22-0175.
    PubMed         Abstract available

    Discov Oncol

  4. SUN J, Wang F, Zhou H, Zhao C, et al
    Downregulation of PGM5 expression correlates with tumor progression and poor prognosis in human prostate cancer.
    Discov Oncol. 2022;13:63.
    PubMed         Abstract available

    Eur Urol

  5. MEISSNER VH, Rauscher I, Schwamborn K, Neumann J, et al
    Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography.
    Eur Urol. 2022;82:156-160.
    PubMed         Abstract available

    Hum Pathol

  6. ABDULFATAH E, Fine SW, Lotan T, Mehra R, et al
    De Novo Neuroendocrine Features in Prostate Cancer.
    Hum Pathol. 2022 Jul 7. pii: S0046-8177(22)00175.

    J Urol

  7. EASTHAM JA, Boorjian SA, Kirkby E
    Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
    J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.

  8. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
    The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
    J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
    PubMed         Abstract available


  9. LI Z, Li B, Yu H, Wang P, et al
    DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
    Oncogene. 2022 Jul 8. pii: 10.1038/s41388-022-02404.
    PubMed         Abstract available

    Ther Adv Urol

  10. FERRO M, de Cobelli O, Musi G, Del Giudice F, et al
    Radiomics in prostate cancer: an up-to-date review.
    Ther Adv Urol. 2022;14:17562872221109020.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.